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doi:10.1016/j.ejvs.2009.04.020Abstract Objective: To identify predictor variables for results after supervised exercise
therapy (SET), and to develop a clinical prediction model that aims to predict a target walking
distance for individual patients.
Design: Retrospective analyses on prospectively collected data.
Materials: Patients with intermittent claudication who participated in a SET programme.
Methods: SETwasconductedaccording to theguidelinesof theRoyalDutchSociety forPhysiotherapy.
Themain outcomemeasurementwas the absolute claudication distance (ACD) after 6months of SET.
Linear regression analyses were conducted to identify independent predictor variables for ACD.
Results: In this cohort, 437 patients were analysed. Independent predictor variables for post-treat-
ment ACD were baseline ACD (P< 0.001), smoking behaviour (PZ 0.012) and body-mass index
(PZ 0.041). A better baseline ACDwas associatedwith a longer post-treatment ACDwhereas current
smoking and a higher body-mass index were associated with a shorter post-treatment ACD. The final
regression equation included baseline ACD, age, body-mass index, smoking and pulmonary disease,
and was translated into several clinical prediction models. However, only 24.8e33.6% of the patients
had an ACD within the calculated target range.
Conclusions: Predictive variables for post-treatment ACD after SETare baseline ACD, age, body-mass
index, pulmonary disease and smoking behaviour. However, translating the regression equation into
a clinical prediction model did not lead to a valid model for use in clinical practice.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.) 40 2399111; fax: þ31 (0) 40 2455035.
.nl (J.A.W. Teijink).
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450 L.M. Kruidenier et al.A common symptom experienced by patients with periph-
eral arterial disease (PAD) is intermittent claudication,
defined as discomfort in the muscles of the lower extrem-
ities that is repeatedly produced by exercise and relieved
when at rest. Complaints of intermittent claudication have
a considerable negative influence on a patient’s walking
ability and quality of life.1e3
Exercise therapy is an effective treatment to increase
walking distance in patients with intermittent claudica-
tion,4,5 and according to a recent Cochrane review, better
results are obtained with supervised exercise therapy (SET)
compared with non-supervised exercise therapy.6
The Dutch physiotherapy guideline, Intermittent Clau-
dication from the Royal Dutch Society for Physiotherapy
provides a practical tool for physiotherapists who supervise
patients in exercise training. According to the guideline, an
increase in maximal walking distance of more than 100%,
evaluated on a treadmill, is considered to be a good result
after SET.7 In a previously conducted cohort study from our
research group, about 48% of patients achieved a good
result and 36% of patients achieved an unsatisfactory result
(<50% improvement) after SET.8
Research on patient-related factors that could influence
the results of SET is scarce.
However, if clinical variables that influence the results
of SET can be identified, it may be possible to identify
a subgroup of patients that will not benefit from SET. As
a consequence, an alternative course of treatment could be
planned for these patients.
We hypothesised that patient-related baseline variables
can influence the results of SET. Therefore, the objective of
this study was to identify clinical predictors of results after
SET and to develop a clinical prediction model based on
patient-related variables that exist at baseline.
Methods
Study population
In patients with a complaint of intermittent claudication
who were referred to the vascular outpatient clinic, the
diagnosis of PAD was confirmed with an ankle-brachial
index (ABI) measurement and/or a duplex ultrasound.
Patients with complaints of intermittent claudication and
confirmation of PAD with an ABI measurement below 0.9 at
rest or decreasing more than 0.15 after exercise were
eligible for community-based SET. Ischaemic pain at rest
and tissue loss were the exclusion criteria for participation
in this community-based SET. Vascular nurse practitioners
admitted the patients and recorded smoking behaviour, co-
morbidities, height, weight and blood pressure. Further-
more, all patients received a prescription for a platelet
inhibitor and lipid-lowering medication (statins).
Data were prospectively recorded in an electronic
patient database developed by the centre of evidence-
based physiotherapy (www.cebp.nl) and Fastguide (www.
fastguide.eu).
All patients who started community-based SET were
potentially eligible for inclusion. Exclusion criteria to
participate in the current study were the inability to walk
the standardised treadmill test, and a baseline ACD of morethan 1600 m. These patients, however, did start community-
based SET.
Registration of the patients’ medical data in the
electronic patient database is part of the usual care
programme, and all patients provided their oral informed
consent to register and use their medical data.
Baseline variables
Smoking behaviour was recorded as current smoker or non-
current smoker (never and previous smokers). Diabetes
mellitus (DM) was considered present if serum fasting
glucose levels were above 7.0 mmol l1 and/or glucose-
lowering medication was prescribed. Hypertension was
defined as the use of blood-pressure-lowering medication
and/or a systolic blood pressure over 140 mmHg. Ortho-
paedic disease was defined as the presence of at least one
of the following: arthrosis, rheumatoid arthritis, poly-
arthritis, osteoporosis or arthroplasty in the lower
extremities. Cardiac disease was considered to be present
in patients with one of the following conditions in their
medical history: angina pectoris, heart failure, myocardial
infarction, coronary arterial bypass graft, percutaneous
transluminal coronary angioplasty, valvular disease or
rhythm disorders. Pulmonary disease was defined as the
presence of at least one of the following: asthma, chronic
obstructive pulmonary disease, emphysema or interstitial
pulmonary disease. Patients with a cerebrovascular acci-
dent or a transient ischaemic attack in their medical history
were considered to have neurological disease.
Supervised exercise therapy programme
All patients received SET according to the guidelines of the
Royal Dutch Society for Physiotherapy7 in a community-
based setting as a part of the usual care programme.
Detailed information on the community-based training
programme is extensively reported previously by our
research group.8e10
Therapy evaluation
Patients were evaluated by their physiotherapist at base-
line and after 1, 3, 6, 9 and 12 months of follow-up. Walking
distances were measured by a standardised, graded,
treadmill test with a constant speed of 3.2 km h1. The
incline starts at 0% and is increased by 2% every 2 min. In
practical considerations, slope and testing duration are
maximised at 10% and 30 min, respectively. Results were
registered by the physiotherapists in the web-based elec-
tronic patient database.
The primary outcome measurement of community-based
SET is the ACD, defined as the distance walked before
a patient is forced to stop exercise. Post-treatment ACD
was measured at least 6 months after the initiation of SET.
Analysis
Categorical variables are presented as frequencies with
percentages. Nominal variables are presented as the
mean standard deviation (normal distribution) or as
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bution. For walking distance, means and standard devia-
tions are reported for the purpose of comparison with the
literature.
Change in walking distance over time in the total cohort
was analysed using repeated measurement analysis of
variance (ANOVA).
Univariable and multivariable linear regression analyses
were conducted to identify the variables predictive of the
absolute post-treatment ACD and the percentage increase
in ACD. In the univariable regression analysis, each variable
is included in a separate regression analysis. In the multi-
variable regression analysis, all pre-specified variables are
included in one regression analysis, using the enter method.
With the enter method, all variables are included in one
step. Pre-specified variables that were included in the
regression models were baseline ACD, age, smoking
behaviour, ABI, BMI, DM, pulmonary disease, neurological
disease, cardiac disease and orthopaedic disease.
Finally, multivariable linear regression analyses using
the backward elimination method were used to identify
the variables included in the final regression equations.
The backward method starts with all the variables in the
equation, and, in every step, variables that do not have
a statistically significant influence are excluded. The
criterion for removal from the regression model was a P
value of more than 0.10. The final regression equations
were formulated to predict post-treatment ACD and
percentage increase in ACD. The regression equation with
best quality was translated into different clinical predic-
tion models to explore the best way to predict post-
treatment ACD. The quality of the regression equation
was described with R2, and lies between 0% and 100%,
with 0% and 100% being worst and best quality, respec-
tively. R2 can be interpreted as the percentage of vari-
ability existing in the original cohort that can be explained
with the included predictor variables in the regression
equation.Table 1 Clinical characteristics of the study population
Characteristica Total population
(NZ 760)
Analysed popu
(NZ 437)
Men 474 (62.4) 266 (60.9)
Age, years 66.0 10.0 65.6 9.9
BMI 26.6 4.4 26.5 4.4
Resting ABI 0.72 0.20 0.71 0.20
SBP, mmHg 156.7 25.1 156.7 26.0
Current smokers 307 (41.3) 180 (42.1)
Hypertension 592 (79.1) 335 (78.1)
DM 221 (29.9) 119 (28.1)
Pulmonary disease 127 (17.3) 71 (16.7)
Neurological disease 106 (14.3) 52 (12.2)
Cardiac disease 260 (34.7) 146 (34.2)
Orthopaedic disease 106 (14.3) 52 (12.2)
Baseline ACDb 390 (240e590) 380 (250e570)
BMI : body-mass index, ABI : ankle-brachial-index, SBP: systolic blo
distance.
a Dichotomous variables are presented as n (%), and continuous var
b Baseline ACD reported as median (interquartile range).The quality of the different clinical prediction models
was tested by comparing the predicted and real values for
each individual patient.
Results
From January 2005 until January 2008, 760 patients met the
inclusion criteria and were included in the study. At 6
months of follow-up, 437 patients (57.5%) were available
for the analysis. For 323 patients, a post-treatment ACD
was not available. These patients discontinued SET early for
the following reasons: co-morbidity (nZ 63, 19.5%), good
result (nZ 26, 8.0%), unsatisfactory result (nZ 32, 9.9%),
insurance/transport problems (nZ 14, 4.3%), not moti-
vated (nZ 38, 11.8%), death (nZ 5, 1.5%), other reasons
(nZ 40, 12.4%), no reason recorded (nZ 105, 32.5%).
There were no significant differences in baseline charac-
teristics between the analysed patients and the patients
who discontinued community-based SET early, as can be
seen in Table 1. Further baseline characteristics of the
study population are also described in Table 1.
The median ACD of the total cohort increased signifi-
cantly (P< 0.001) from 380 (IQR: 250e570) m at baseline
(mean SD, 449 292 m) to a median of 850 (IQR: 505e
1600) m post-treatment (mean SD, 949 495 m). More
details on walking distance can be found in Table 2.
Clinical predictors for post-treatment ACD
In Table 3, the associations between the different baseline
characteristics with post-treatment ACD are presented. In
the multivariable regression analysis that included all
selected variables, baseline ACD (P< 0.001) and current
smoking (PZ .008) were independent predictor variables
for post-treatment ACD. A better baseline ACD was asso-
ciated with a longer post-treatment ACD, whereas current
smoking was associated with a lower post-treatment ACD.lation Early dropouts
(NZ 323)
P-value Missing
values n (%)
208 (64.4) 0.321 e
66.6 10.0 0.170 5 (0.7)
26.8 4.4 0.316 45 (5.9)
0.72 0.21 0.815 66 (8.7)
156.7 24.0 0.998 59 (7.8)
127 (40.3) 0.634 17 (2.2)
257 (80.6) 0.410 12 (1.6)
102 (32.3) 0.216 20 (2.6)
56 (17.9) 0.669 24 (3.2)
54 (17.1) 0.062 19 (2.5)
112 (34.9) 0.911 10 (1.3)
54 (17.1) 0.058 17 (2.2)
400 (220e600) 0.574 e
od pressure, DM: diabetes mellitus, ACD: absolute claudication
iables as mean standard deviation, unless otherwise indicated.
Table 2 Median absolute claudication distance for the
total cohort
Follow-up N Absolute ACD,a m
median (interquartile
range)
Absolute increase
in ACD, m median
(interquartile range)
Baseline 437 380 (250e570) e
1 month 339 620 (420e900) 190 (64e360)
3 months 348 725 (512e1170) 320 (130e590)
6 months 437 850 (505e1600) 390 (188e805)
ACD, absolute claudication distance.
a P value< .001 for the increase in ACD.
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10 variables.
The final regression equation had a R2 of 29.4% with five
variables instead of 10. Baseline ACD (P< 0.001), current
smoking (PZ 0.012) and BMI (PZ 0.041) were significant
predictors. Besides these variables, the final regression
equation for post-treatment ACD consisted of age, and
pulmonary disease. In the final regression equation,
a better baseline ACD was associated with a better post-
treatment ACD whereas older age, current smoking, higher
BMI and presence of pulmonary disease were associated
with a lower post-treatment ACD.
The following regression equation was determined:
ACDposttreatmentZ 1218 þ 0:9  ACDbaseline  5
Age  11  BMI  124  Currentsmoking
 114  Pulmonarydisease:
For baseline ACD, age BMI, smoking behaviour and
pulmonary disease, the baseline values of an individualTable 3 Regression models for post-treatment absolute claudic
Variables Univariable regression Mul
P value Beta per unitc P va
Total model e e <.0
Continuous variables
Baseline ACD <.001 0.899 <.0
Age <.001 9.831 .1
ABI .104 203.587 .2
Body-mass-index .179 7.424 .1
Dichotomous variables
Current smoking .120 75.523 .0
DM .004 154.867 .2
Pulmonary disease .005 180.826 .0
Neurological disease .069 133.317 .7
Cardiac disease .242 58.777 .3
Orthopaedic disease .096 121.533 .7
ACD, absolute claudication distance, ABI, ankle-brachial-index, DM, d
a R2Z 29.3%.
b R2Z 29.4%.
c The beta gives information about the direction of the association a
the bigger the influence per unit on the dependant variable.patient can be inserted into the regression equation to
calculate post-treatment ACD. For the dichotomous vari-
ables, 0 means the condition is not present and 1 means
that the condition is present.
Clinical predictors of percentage increase in ACD
The associations of the different baseline characteristics
with percentage increase in ACD are presented in Table 4.
In the multivariable regression analysis that included all
pre-specified variables, baseline ACD (P< 0.001) and BMI
(PZ 0.022) were independent predictors for percentage
increase in ACD. The multivariable regression model that
included all 10 variables had a R2 of 0.94%.
The final regression model had a R2 of 10.7% with
inclusion of baseline ACD (P< 0.001) and BMI (PZ .022) as
the only variables. Both variables had a negative associa-
tion with percentage increase in ACD, indicating that
a lower baseline ACD and a lower BMI were associated with
a higher percentage increase in ACD. The regression
equation derived from this model is:
PercentageincreaseACDZ 653  0:4
 ACDbaseline  11  BMI:
For baseline ACD and BMI, the baseline values of an
individual patient can be inserted into the regression
equation to calculate percentage increase in ACD.
Clinical prediction model for post-treatment ACD
The regression equation for post-treatment ACD was
translated into several clinical prediction models, which
included all variables of the final regression model, and
aimed to predict a target ACD for each patient. However,
even in the original cohort, only 24.8e33.6% of the patientsation distance
tivariable regressiona Final regressionb
lue Beta per unitc P value Beta per unitc
01 e <.001 e
01 0.858 <.001 0.879
10 4.092 .062 4.686
21 137.813 e e
19 8.597 .041 10.760
08 134.110 .012 123.708
00 67.973 e e
71 110.014 .059 114.194
48 22.277 e e
26 49.195 e e
04 27.099 e e
iabetes mellitus.
nd the influence of each individual variable. The bigger the beta,
Table 4 Regression models for percentage increase in absolute claudication distance
Variables Univariable regression Multivariable regressiona Final regressionb
P value Beta per unitc P value Beta per unitc P value Beta per unitc
Total model e e <.001 e <.001 e
Continuous variables
Baseline ACD <.001 0.632 <.001 0.392 <.001 0.397
Age .334 3.601 .778 0.587 e e
ABI .129 306.938 .920 9.253 e e
Body-mass-index .017 9.191 .022 10.335 .007 11.076
Dichotomous variables
Current smoking .819 13.902 .866 6.902 e e
DM .730 29.157 .452 32.440 e e
Pulmonary disease .757 31.477 .957 2.661 e e
Neurological disease .038 239.866 .288 60.182 e e
Cardiac disease .750 25.151 .922 4.003 e e
Orthopaedic disease .904 13.923 .297 60.535 e e
ACD, absolute claudication distance; ABI, ankle-brachial-index; DM, diabetes mellitus.
a R2Z 0.94%.
b R2Z 10.7%.
c The beta gives information about the direction of the association and the influence of each individual variable. The bigger the beta,
the bigger the influence per unit on the dependant variable.
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range.
Discussion
This study shows that baseline ACD is the strongest
predictive variable for post-treatment ACD as well as
percentage increase in ACD, although the correlations are
in the opposite direction. A higher baseline ACD predicts for
a longer post-treatment ACD, but a lower percentage
increase in ACD. Besides baseline ACD, other independent
predictor variables were BMI and current smoking for post-
treatment ACD and BMI for percentage increase in ACD.
In literature, several studies can be found about clinical
variables that predict treatment outcome. In line with our
study, Andriessen et al.11 and Rosfors et al.12 found that
baseline ACD was an independent predictor for ACD after
a SET program.
However, Lundgren et al.13 and Gardner et al.14 found no
independent association between the baseline walking
distance with post-treatment ACD after SET in patients with
intermittent claudication. Possible explanation for this
difference is that sample sizes are very small in comparison
with our study.
Other proposed predictor variables from the literature
are walk symptoms on baseline and toe pressure to predict
walk symptoms after treatment.15 Furthermore, Amighi
et al.16 found that the female sex, diabetes and a low ABI
were associated with less clinical improvement after
conservative treatment of intermittent claudication.
Based on the regression equation for post-treatment
ACD, we developed several clinical prediction models to
calculate a minimum and maximum expected post-treat-
ment ACD for an individual patient. However, using varying
clinical models, maximal one-third of the cases was pre-
dicted correctly. In our opinion, the quality of the differentclinical prediction models that we have tried is poor and
the prediction based on the baseline variables in the final
regression equation is not accurate. This indicates that
besides the variables discussed, other factors influence
a large part of treatment outcome. Therefore, a clinical
prediction model, based on baseline ACD, age, smoking
behaviour, BMI and pulmonary disease, does not seems
sufficient for use in clinical practice.
Other possible factors influencing treatment outcome
could be related to training, the level of occlusive disease
or cognitive factors.
Cheetham et al.17 found that walking more frequently
was associated with a better result. Furthermore, Gardner
and Poehlman18 found that 87% of the variance in increase
in ACD was explained by training-related factors. In this
study, training to near-maximal pain, a programme of at
least 6 months and walking as the main mode of exercise
were associated with more increase in ACD. In our cohort,
these exercise components may also have had a predictive
value for post-treatment ACD. The guideline from the Royal
Dutch Society for Physiotherapy provides general instruc-
tions about treatment components that are adapted by
a physiotherapist for every patient. Therefore, in our study,
variation exists in the frequency, length of the programme
and mode of exercise.
In this study, the level of occlusive disease was not
studied. However, there are some indications that SET is
more effective in femoral disease compared with more
proximal disease.19 Additional research to study the asso-
ciation of the after-SET results with the level of occlusive
disease would be interesting.
The patient’s belief that training is beneficial for their
disease is positively associated with the percentage
increase in walking distance,12 and presence of depressive
symptoms is negatively associated with ACD.20 Further-
more, patients with a type D personality (a tendency to
454 L.M. Kruidenier et al.have negative feelings combined with a lack of expression
of those feelings) remain more impaired after conservative
or invasive treatment compared with non-type D patients
with intermittent claudication.21 However, these cognitive
factors were not registered in our study. Regression anal-
yses that include these variables would be interesting in
future research.
Limitations of the study
A major limitation of the study was that for many patients
no post-treatment ACD was available because of a high
number of patients who discontinued SET within the first 6
months. A total of 323 patients (42.5%) discontinued with
the training programme before 6 months of follow-up. This
could have caused a bias in our analysis, assuming that
patients who did not continue with the training programme
would have relatively poor results. This could lead to
underestimation of the negative influence from age, BMI,
current smoking and pulmonary disease. However, no
statistical significant differences in baseline variables
existed between the analysed population and the dropouts.
In literature, the drop-out percentages range from 10%
to 50% within 6 months of SET in randomised controlled
studies.22e26 In our study, a corresponding drop-out
percentage was found (42.5%) in a setting describing
a regular care programme instead of a controlled study.
These percentages are also in line with the previous
reported results of community-based SET.8,9
A second limitation of this study is that we did not record
the exact training programme for the individual patients.
According to the Dutch Physiotherapy guideline, general
instructions for therapy components were adapted by the
physiotherapist for the individual patient. Therefore,
the possible influence of variation in therapy components on
theoutcomeof SETcannot bedetermined in the current study.
Implications for clinical practice
In general, SET is a safe and effective treatment for
patients with intermittent claudication, although not all
patients benefit from a training programme.8 If we could
identify a group of patients who are less likely to benefit
from SET, early adaptations to the treatment plan could be
made. However, our study shows that a valid prediction of
the SET results is not possible based on simple clinical
baseline variables. As long as we cannot adequately predict
if patients will or will not benefit from SET, starting with
SET as the primary treatment should be the first option for
all patients with intermittent claudication. When SET does
not lead to sufficient relief of symptoms, other treatment
options are still available.
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